Boston Scientific had its Relative Strength (RS) Rating upgraded from 69 to 72 Wednesday — a welcome improvement, but still short of the 80 or higher score you prefer to see.
Can You Really Time The Stock Market?
IBD's unique rating measures share price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if Boston Scientific can continue to rebound and hit that benchmark.
While the stock is not near an ideal buy point right now, see if it manages to form and break out of a proper chart pattern.
Earnings growth slowed last quarter from 34% to 21%. But revenue moved higher, from 21% to 23%.
The company holds the No. 5 rank among its peers in the Medical-Products industry group. Insulet is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
